SPY317.59+3.21 1.02%
DIA260.82+3.58 1.39%
IXIC10,617.44+69.69 0.66%

Exelixis Announces Initiation Of CONTACT-02 Phase 3 Trial Of Cabozantinib In Combination With Atezolizumab In Previously Treated Metastatic Castration-Resistant Prostate Cancer

– Initiation follows positive results from cohort 6 of phase 1b COSMIC-021 trial – – CONTACT-02 is the second of three phase 3 pivotal trials that are part of a clinical collaboration

Benzinga · -

– Initiation follows positive results from cohort 6 of phase 1b COSMIC-021 trial –

– CONTACT-02 is the second of three phase 3 pivotal trials that are part of a clinical collaboration with Roche –